3rd International Symposium on Veterinary Pharmacovigilance Berlin, 13-14th December 2010

Similar documents
PRESS RELEASE COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

Reflection paper on promotion of pharmacovigilance reporting

Presentation of ANSES

Standard operating procedure

Recommendation for the basic surveillance of Eudravigilance Veterinary data

PRESS RELEASE COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE Meeting of 12 to 14 October 2004

Giles Davis., BVSc., GPCertSAP,, MRCVS

Veterinary Pharmacovigilance

Focus group on promotion of PhV for food producing animals MAH view. IFAH-Europe Tony Simon 23rd November 2016

Public bulletin - Veterinary pharmacovigilance 2010

PRESS RELEASE COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE Meeting of 13 to 15 July 2004

VICH GL30 on pharmacovigilance of veterinary medicinal products: controlled list of terms

International Harmonisation in the Field of Pharmacovigilance from an OIE perspective

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE

Opinion of the Committee for Medicinal Products for Veterinary Use pursuant to Article 30(3) of Regulation (EC) No 726/2004

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE. Monthly Report of Application Procedures, Guidelines and Related Documents

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE. Monthly Report of Application Procedures, Guidelines and Related Documents

Assessment of compliance of current legislation: Veterinary Products Act

Further memorandum submitted by the Department for Environment, Food and Rural Affairs

Legislation on Veterinary Medicinal Products (VMPs) and legal status of relevant VMPs for anesthesia of finfish

Scientific Discussion post-authorisation update for Rheumocam extension X/007

Draft ESVAC Vision and Strategy

OIE Standards for: Animal identification and traceability Antimicrobials

Dr. Gérard Moulin AFSSA/ANMV OIE Collaborating Centre on Veterinary medicinal products BP FOUGERES CEDEX, FRANCE

Council of the European Union Brussels, 13 June 2016 (OR. en)

Scientific and technical support NOTE of the French Agency for Food, Environmental and Occupational Health & Safety

Results of the questionnaire on Veterinary Medicinal Products in the Middle East Damascus, Syria, 2-4 December 2009

The impact of Good Veterinary Services Governance (GVSG) on the control over Veterinary Medicinal Products (VMP s)

Olivier FAUGERE DVM - Director National School for Veterinary Services - ENSV

Diclofenac in Europe an update

Sales survey of Veterinary Medicinal Products containing Antimicrobials in France

Veterinary pharmacovigilance 2014

Physician Veterinarian Do you have the Bayer Spirit?

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

OIE standards on the use of antimicrobials and antimicrobial resistance monitoring

Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of July 2016

Committee for Medicinal Products for Veterinary Use (CVMP) Work Plan 2018

VETERINARY MEDICINE-VM (VM)

21st Conference of the OIE Regional Commission for Europe. Avila (Spain), 28 September 1 October 2004

Quality of Veterinary Medicinal Products. How to ensure the quality of Veterinary Medicinal Products

Action for Combatting AMR in Veterinary Sector

Veterinary pharmacovigilance 2016

PRESS RELEASE COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE Meeting of 7-9 November 2006

Workshop on Strengthening livestock health and Veterinary Services. Kiev, 2-3 November 2010 TAIEX, AGR 42266

Sales survey of Veterinary Medicinal Products containing Antimicrobials in France Volumes and estimated exposure of animals to antimicrobials

Legislation, Registration and Control Procedures for Veterinary Medicinal Products in the European Union

OIE Strategy on Antimicrobial Resistance and the Prudent Use of Antimicrobials in Animals Part I

Agvet Chemicals Task Group Veterinary Prescribing and Compounding Rights Working Group

Ambassade de France en Chine. The French Food Safety System

Prudent use of antimicrobial agents Dairy Sector Initiatives. Robin Condron Dairy Australia

Highlights on Hong Kong Strategy and Action Plan on Antimicrobial Resistance ( ) (Action Plan)

PRESS RELEASE COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE

Veterinarians and Bee Health involvement taking France as an example

Contents & results of 3 years of VMP FP training Susanne Münstermann OIE Scientific and Technical Department

Actions for combatting Antimicrobial Resistance (AMR)

Better Training for Safer Food

Specificities of Products for Veterinary Use

Standard operating procedure

HMA-V Action plan on antimicrobial issues Version for publication (27 January 2011)

EFSA s activities on Antimicrobial resistance in the food chain. Dr. Ernesto Liebana Head of BIOCONTAM Unit. EFSA

All medicinal products (for human and veterinary use) are regulated under the single Pharmaceutical Act.

Antimicrobial Resistance Actions undertaken by the Anses (alternatives to AM)

Antimicrobial resistance in food safety perspective - current situation in Croatia

08/09/2009. Constraints for the livestock industry in Zambia. Veterinary Education and Curriculum Development: Zambia (Lusaka)

Regional Analysis of the OIE PVS Missions in South-East Asia with a focus on APFS

international news RECOMMENDATIONS

OIE GLOBAL DATABASE ON AMU IN ANIMALS

An agency of the European Union

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised

Monthly report on application procedures, guidelines and related documents for veterinary medicines

FACULTAT DE VETERINÀRIA DE BARCELONA

ANNUAL DECLARATION OF INTERESTS (ADoI)

CODE OF PRACTICE TO MINIMIZE AND CONTAIN ANTIMICROBIAL RESISTANCE CAC/RCP Adopted 2005

Proposal for a Regulation on veterinary medicinal products

EMA advice on the impact of the use of antibiotics on public and animal health: Potential impact on the authorisation of antimicrobials

COUNTRY REPORT THAILAND. Sasi Jaroenpoj Department of Livestock Development

Overview of the OIE PVS Pathway

AUDIT REPORT. Auditor(s) UFPAL

Stephane MARTINOT Past dean of VetAgro Sup (Lyon, France) Challenges for accreditation: how to harmonise mechanisms at the global level and how to

Responsible use of antimicrobials in veterinary practice

Illegal veterinary drugs. How to ensure the quality and traceability of Veterinary Medicinal Products

Sales survey of veterinary medicinal products containing antimicrobials in France in Annual report

The European Union Reference Laboratories network

NASH Analysis Lab. Report of the audit. Prepared by: NASH Analysis Lab. CEO: Ni Ni Win. Quality manager: AgnieszkaPaszkowska

OIE stray dog control standards and perspective. Dr. Stanislav Ralchev

Support for OIE Member Countries OIE PVS / Gap Analysis, Reference Laboratories and twinning programmes

Stratégie et action européennes

China Training Seminar on the OIE PVS Tool for East Asia Seoul, Republic of Korea, April 2016

EPAR type II variation for Metacam

National Action Plan development support tools

Surveillance of animal brucellosis

Annual Report in accordance with Article 13, paragraph 4

REZIDUE CONTROL IN SERBIA & MRLs

BTSF. Better Training for Safer Food Initiative. Antimicrobial Resistance One Health approach MEASURE UNITS

COMMISSION. (Text with EEA relevance) (2009/712/EC)

OIE Collaborating Centres Reports Activities

Introduction SEAVDRAC. 23 October Prof G E Swan. Southern and Eastern African Veterinary Drug Regulatory Affairs conference

Review of Legislation for Veterinary Medicinal Products Version 2

Dr A T Sigobodhla. Regional Workshop for OIE National Focal Points for Veterinary Products (Cycle V): Ezulwini, Swaziland, 6-8 December 2017

Transcription:

Veterinary Pharmacovigilance Centres: the French experience 3rd International Symposium on Veterinary Pharmacovigilance Berlin, 13-14th December 2010 Xavier Pineau*, Florence Roque*, Stéphane Queffélec*, Christophe Hugnet** *Veterinary Pharmacovigilance Centre of Lyon VetAgro Sup - Veterinary Campus of Lyon **Clin vét. des Lavandes, La Bégude de Mazenc

Veterinary Pharmacovigilance in France: current organisation Legislative background decree 99/553, amended 2003/760 and 2004/802 (2010-871: effect in 2011) Included in Public health codex, Rural affairs codex Actors CA = ANMV: French Agency of VMPs, under responsibility of ANSES (French Agency for Food, Environmental and Occupational Health&Safety ) / Ministry of Agriculture, Ministry of Health Veterinary Pharmacovigilance Center (formerly 2 VPCs, currently 1) National Veterinary Pharmacovigilance Commitee Representatives of CA, VPC, veterinarians, pharmacists, pharmaceutial companies trade union Reporters MAHs Reporting Scheme adapted from Human PV 29 Regional PV Centres, National PV Committee, PV technical Committee VPC of Lyon Created 2001, but in close cooperation with National Animal Poison Control Center (CNITV) created in 1976 Contract between ANSES and VetAgro Sup (formerly Vet School of Lyon)

Pharmacovigilance reporting: French legislation Veterinarians (and pharmacists) (Art. R5141-103 of public health codex) must report immediately to a Veterinary Pharmacovigilance Centre (VPC) any serious or unexpected suspected adverse reaction to a Veterinary Medicinal Product (VMP), or to a human medicine in animal (used under the «cascade») ; regardless VMP prescribed or not by reporter, and regardless adverse reaction observed directly by vet or not may report other adverse events (non-serious SAR, off-label use, withdrawal period issue, lack of expected efficacy) Health care professionals may report suspected adverse reaction to a VMP to a VPC Poison Control Centres and (human) Regional Pharmacovigilance Centres must report immediately to a VPC any suspected adverse reaction to a Veterinary Medicinal Product (VMP) occuring in humans

the French Veterinary Pharmacovigilance Reporting Scheme Health Care Professionals Regional Pharmacovigilance Centres Poison Control Centres e-reporting (web) Veterinarians (Pharmacists) ANMV SARs PSURs MAH National Committee of Veterinary Pharmacovigilance information -reports -newsletter National Marketing Authorisation Committee Corrective measures -SPC modifications -MA suspension

VPC: an interactive interface between reporters and CA (1) 1/ phone contact (85%) round the clock hotline (shared with Poison Control Centre) immediate answer to reporter first estimation of causality therapy, prognosis Vets Physicians Pharmacists also questions related to asymptomatic (accidental) exposures in animals/humans drug use in particular species, breed, physiological status, interaction

VPC: an interactive interface between reporters and CA(2) Vets Physicians Pharmacists 2/ in writing spontaneous report form (15%) report form received after phone contact (46% returned back) VPC letter to the reporter, including: final VPC causality assessment comment exception: BTV cases managed directly by the Agency

VPC: an interactive interface between reporters and CA(3) Vets Physicians Pharmacists 3/ VPC and the Agency report form (from phone call/written report) recorded in database (Sentinelvet ) causality assessment performed (literature, comparison with db) electronic reporting to the Agency (secure web) serious SAR within 10 days non-serious SAR within 3 months

VPC: inside Veterinary Campus round the clock service: involvement of selected trained students practical teaching exercise: students are faced «real-life cases» learn autonomy (senior pharmacovigilance vet always available) know-how (reporting, bibliographic search) highlighted in international audits of the Vet Campus AEEV AVMA first line for promoting pharmacovigilance for future vets in cooperation with teachers basic course (all students) end-study (e.g horse medicine)

graduation veterinary thesis VPC: inside Veterinary Campus (2) Delhaye D. Side effects and poisoning due to the use of medicines containing permethrin on cats. Epidemiological study (2008): http://www3.vet-lyon.fr/bib/fondoc/th_sout/dl.php?file=2008lyon018.pdf (in French) Gedoux F. Problem of drug residues in food of vultures, especially anti-inflammatory drugs, antibiotics and euthanasia drugs used in livestock (2010) http://www3.vet-lyon.fr/bib/fondoc/th_sout/dl.php?file=2010lyon062.pdf (in French) postgraduate education 2002-2006: Pharmacovigilance-Toxicovigilance Master to be conducted again? cooperation with colleagues of various teaching/research areas (inside Campus / other Vet Schools) Several teachers/researchers involved in National PV Committee over the last 9 years Pr Keck (Lyon), former Chairman Dr Alvinerie (Toulouse), current Chairman helpful for scientific evaluation, where necessary e.g toxicological analysis lab of Lyon, Pharmacology Unit of Toulouse provide some valuable case reports e.g Cardiology Unit of Alfort Vet School

VPC: key figures. 1/ reporting way, yearly distribution 4000 3500 3000 2500 2000 1500 1000 BTV I AsE WR* NV-tel* V-tel* Most reports by telephone over 85% (except BTV) Vets: near 90% of reports; pharmacists 0.3%; owner 6.5% Continuous increase until plateau phase BTV excepted 500 0 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 V-tel*: phone call, veterinary reporters (BTV excluded) NV-tel*: phone call, non-veterinary reporters (BTV excluded): owner, physician, PCC WR*: spontaneous written report (BTV excluded) AsE: Asymptomatic exposure I: general information BTV: Bluetongue vaccination adverse events

VPC: key figures. 2/ Species - yearly distribution 3500 3000 2500 2000 1500 1000 500 Other Rabbit Ovine Equine Human Bovine Canine Feline Companion animals: over 85% Livestock increase of ruminants: BTV only (cattle 3% for other classes of VMPs) pigs and poultry: negligible numbers 0 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010

VPC: key figures. 3/ VMP category - yearly distribution (ATC-vet) 3500 3000 2500 2000 1500 1000 500 Others Dermatologicals&Sensory organs Hormones&Corticoids Alimentary Musculo-skeletal Neurological Antibiotic Vaccine Internal Parasiticide Endectocide Majority of parasiticides 30-60% decrease of external parasiticides (mainly: permethrin spot in cats) Vaccines increase = BTV vaccines other vaccines#3-5% 0 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 External Parasiticide

VPC: involved in national committees National Veterinary Pharmacovigilance Committee 3 vets of VPC members of this Committee (2001-2010) 2002-2008, the Committee released 19 public reports (in French) http://www.anmv.anses.fr/pharmacovigilan ce/rubrique%20lettre.htm Summarized in 7 PV newsletters sent to all vets and pharmacists Toxicovigilance network (human safety scheme) contribution to reports e.g clenbuterol misuse in humans (2010) http://www.centresantipoison.net/cctv/rapport_cctv_clen buterol_2010.pdf (in French)

VPC: international cooperation VPC: participation to EMA-PhVWP 1 vet as expert (2001-2010) contributions regarding causality assessment, signal detection, Veddra VPC: informal contacts with other countries Switzerland Italy Spain

Advantages of the French Reporting System / VPC Advantages for Reporters round the clock service for emergency situations (e.g overdose): availability pharmacovigilance reporting as easy as a phone call other options available (mail, e-mail, fax, and since early 2010 web reporting directly to the ANMV) feed-back tailored answer (oral/in writing) newsletter from Committee Advantages for Reporting scheme Direct contact increases quality of data (spontaneous written reports usually less informative)

Drawbacks of the French Reporting System / VPC Cost round the clock service 3 full-time vets (cost supported by ANSES) 0.5 secretary (cost supported by ANSES) 0.75 librarian (cost supported by ANSES) 45 students (equivalent to 1 full time vet; cost supported by Poison Control Centre) at start (2001) network of 2 VPCs Dec 2008,VPC of Nantes closed

Perspectives of the French Pharmacovigilance Scheme 2011 Committee of Marketing Autorisation of VMPs and Veterinary Pharmacovigilance Committee merge into a Committee of VMPs (come into effect January 2011) 5 representatives of CA, 18 nominated members (pharmacologists, vets, ) expected benefit: quicker implementation of recommendations (e.g modifications of SPC) Network of «sentinel veterinarians» in the field of pharmacovigilance, for targeted surveillance (e.g for BTV vaccines or any rising issue) Postmarketing studies case-control studies (e.g mammary tumours and progestins; report of the PV Committee estimated a high level of underreporting)

Thank you for your attention Vielen Dank zu Cornelia Ibrahim und zum BVL